Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles.
Recent efforts to design an human immunodeficiency virus type 1 (HIV-1) vaccine candidate have focused on means of eliciting anti-viral T-cell responses. We tried to improve the immunogenicity of DNA vaccines by designing hybrid DNA constructs encoding hepatitis B surface antigen (HBsAg) fused to antigenic domains of simian/human immunodeficiency virus (SHIV 89.6P). Immunisation with hybrid DNA induced both effector and long-lasting precursor T-cells. Following boosting with a recombinant modified vaccinia Ankara (rMVA) producing full-length SIV and HIV antigens, it appeared that priming with hybrid DNA had increased virus-specific T-cell responses in terms of both the number of virus-specific IFN-gamma-secreting T-cells and virus-specific lymphoproliferation. After intrarectal challenge with SHIV 89.6P, immunised animals demonstrated early control of SHIV 89.6P replication and stable CD4+ T-cell counts.
INSERM U 370, Carcinogenèse Hépatique et Virologie Moléculaire, Département de Médecine Moléculaire, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France.
Anne-Laure
AL
Puaux
Delphine
D
Marsac
Stéphane
S
Prost
Mandal K
MK
Singh
Patricia
P
Earl
Bernard
B
Moss
Roger
R
Le Grand
Yves
Y
Riviere
Marie-Louise
ML
Michel
D016915:AIDS Vaccines / Q000627:therapeutic use*; D000818:Animals; D019540:Area Under Curve; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002455:Cell Division / Q000187:drug effects; D003587:Cytomegalovirus / Q000235:genetics; D004247:DNA / Q000235:genetics* / Q000276:immunology*; D015342:DNA Probes; D004797:Enzyme-Linked Immunosorbent Assay; D005822:Genetic Vectors; D006678:HIV / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000235:genetics / Q000276:immunology*; D007117:Immunization, Secondary; D007371:Interferon-gamma; D007700:Kinetics; D008253:Macaca mulatta; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018449:SAIDS Vaccines / Q000627:therapeutic use*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D019444:Vaccines, DNA / Q000627:therapeutic use; D022223:Vaccines, Subunit / Q000627:therapeutic use; D014615:Vaccinia / Q000276:immunology; D014779:Virus Replication
D016915:AIDS Vaccines; D015342:DNA Probes; D006514:Hepatitis B Surface Antigens; D018449:SAIDS Vaccines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D007371:Interferon-gamma; D004247:DNA